ArticleBMC microbiology2026
Longitudinal analysis of postoperative chemotherapy on oral-gut microbiota in patients with advanced gastric cancer.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond antibiotics: collateral damage to the gut microbiome during cancer therapy.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGut microbiota plays a pivotal role in modulating therapeutic responses in malignancies. Elucidating microbial dynamics during cancer treatment provides critical insights for optimizing therapeutic strategies and prognostic prediction. PURPOSE: To investigate longitudinal alterations in oral and gut microbiota during chemotherapy in advanced gastric cancer (GC) patients and their prognostic implications.
methodsThis study enrolled 29 advanced GC patients, with tongue coating and fecal samples collected before the 1st (GC0), 2nd (GC1), and 3rd (GC2) chemotherapy cycles, alongside 35 healthy controls. Bacterial communities were profiled via 16 S rRNA V3-V4 sequencing, and fungal communities via 18 S rRNA ITS1-ITS2 sequencing. LEfSe, ROC analysis, Zero-Inflated Beta Regression (ZIBR) modeling, and co-occurrence network analysis were employed to evaluate microbial dynamics and prognostic utility.
resultsDuring chemotherapy, oral fungal and gut bacterial richness (ACE and Chao indices) significantly decreased, while gut fungal richness increased. β-diversity analysis revealed minimal structural alterations in oral-gut microbiota. The abundance of intestinal bacterial Subdoligranulum genus and the fungal Candida (in both intestine and oral cavity) exhibited a decreasing trend, whereas the abundance of intestinal bacterial genera including Escherichia-Shigella and Streptococcus significantly increased (P < 0.05) during chemotherapy in patients with advanced GC. In the GC0 group, 23 genera (e.g., oral/gut Bacillus, oral Veillonella) predicted 12-month progression-free survival (PFS) (AUC > 0.7). Longitudinal analysis identified 25 genera (e.g., oral Clostridium_sensu_stricto_1, gut Bacillus and Howardella) significantly associated with PFS across GC0-GC2 (Joint P < 0.05). Co-occurrence networks demonstrated oral bacterial dominance in GC patients, with chemotherapy reducing network complexity.
conclusionContinuous chemotherapy exerted significant effects on the oral-gut microbiota co-occurrence networks in advanced GC patients, with pre-chemotherapy microbiota demonstrating prognostic diagnostic value. This study provided microbiological evidence to inform future GC monitoring and personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.